Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology.
At the this year’s edition of the TOP 100 Swiss Startup Award, where Switzerland’s best startups with the greatest potential are celebrated, Araris ranks TOP14!
It is now the fifth year in a row, starting 2019, that Araris is selected by a Jury of investors and startup experts.
What a great success for Araris, after positions 19 in 2022 and 11 in 2021.
We congratulate Philipp Spycher (CEO) and his team for this great achievement!
https://www.ararisbiotech.com/
Araris made it to TOP11 in this year's edition of the TOP 100 Swiss Startup Award.